Capecitabine NDC 59651-205

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-205Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0205Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-205-08	59651020508	120 TABLET in 1 BOTTLE (59651-205-08)Marketed from Apr 17, 2018
59651-205-10	59651020510	1 BLISTER PACK in 1 CARTON (59651-205-10) / 10 TABLET in 1 BLISTER PACKMarketed from Apr 17, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Capecitabine
Generic name (nonproprietary): capecitabine
Active ingredients: Capecitabine — 500 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210604
Marketing start: Apr 17, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 59651-205_eee71cc5-a7d5-4e51-ab02-2fae12418585SPL ID eee71cc5-a7d5-4e51-ab02-2fae12418585SPL set ID 56441153-a1e5-4fdc-96d6-f21baa6b5fbeRxCUI 200327, 200328UNII 6804DJ8Z9U
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651020508 followed by a unit qualifier and the quantity

Package 59651-0205-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 8, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Capecitabine tablets are a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patient…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210604

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210604
Product	Strength	Form · route	Labeler	Product NDC
Capecitabine	Capecitabine 150 mg/1	TabletOral	Aurobindo Pharma Limited	59651-204